Cisplatin and AZD2281 have been shown to cooperate in the treatment of BRCA-1 deficient mammary tumors in vivo[43], and PARP inhibitors enhance cancer cell sensitivity to radiation and alkylating agents [50]. Here, PARP1 is linked to cancer.